These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32835535)

  • 1. Clopidogrel drug interactions: a review of the evidence and clinical implications.
    Lee CH; Franchi F; Angiolillo DJ
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1079-1096. PubMed ID: 32835535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Alternative Antiplatelet Agents for Clopidogrel Hypersensitivity.
    Ather A; Beavers CJ
    Curr Vasc Pharmacol; 2019; 17(2):127-132. PubMed ID: 30058492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of clopidogrel.
    Sarafoff N; Byrne RA; Sibbing D
    Curr Pharm Des; 2012; 18(33):5224-39. PubMed ID: 22724411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends for and Clinical Factors Associated with Choice of Oral P2Y
    Jain N; Hunt SL; Cui H; Phadnis MA; Mahnken JD; Shireman TI; Dai J; Mehta JL; Rasu RS
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):511-521. PubMed ID: 31729588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Clopidogrel Hypersensitivity: The Jefferson Approach.
    Vishnevsky A; Savage MP; Fischman DL
    Curr Vasc Pharmacol; 2019; 17(2):123-126. PubMed ID: 30058491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
    Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
    EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing Clopidogrel Hypersensitivity without Interrupting Therapy: The Toronto Approach.
    Cheema AN
    Curr Vasc Pharmacol; 2019; 17(2):119-122. PubMed ID: 30124155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Potent Oral P2Y
    Ma S; Li Z; Yu P; Song H; Jiang Z; Li Y; Han Y
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):199-208. PubMed ID: 32006144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation.
    Shimamatsu J; Sasaki KI; Katsuki Y; Kawasaki T; Murasato Y; Ajisaka H; Yokoi H; Tashiro H; Harada A; Hirakawa Y; Ishizaki Y; Ishimatsu T; Kagiyama K; Fukumoto Y; Kakuma T; Ueno T
    Heart Vessels; 2020 Mar; 35(3):312-322. PubMed ID: 31549178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant use of drugs known to cause interactions with oral antiplatelets-polypharmacy in acute coronary syndrome outpatients in Finland.
    Prami T; Khanfir H; Hasvold P; Reissell E; Airaksinen J; Kytö V
    Eur J Clin Pharmacol; 2020 Feb; 76(2):257-265. PubMed ID: 31773191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention.
    Piqueras-Flores J; Jurado-Román A; López-Lluva MT; Sánchez-Pérez I; Abellán-Huerta J; Lozano-Ruiz Poveda F
    J Cardiovasc Pharmacol; 2019 Jan; 73(1):56-59. PubMed ID: 30383607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study.
    Kitano D; Takayama T; Fukamachi D; Migita S; Morikawa T; Tamaki T; Kojima K; Mineki T; Murata N; Akutsu N; Sudo M; Hiro T; Hirayama A; Okumura Y
    Catheter Cardiovasc Interv; 2020 Jan; 95(1):E8-E16. PubMed ID: 30983087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of acenocoumarol on the antiplatelet effect of clopidogrel.
    Dewilde WJ; Janssen PW; Bergmeijer TO; Kelder JC; Hackeng CM; ten Berg JM
    Thromb Haemost; 2015 Oct; 114(4):708-16. PubMed ID: 26177793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-Analysis Comparing Potent Oral P2Y
    Casula M; Fortuni F; Ferlini M; Fabris F; Oltrona Visconti L; Leonardi S
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):231-240. PubMed ID: 32895853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry.
    Lupi A; Bona RD; Meliga E; Capodanno D; Schaffer A; Bongo AS; Gaudio G; Guasti L; Alexopoulos D; Valgimigli M; Porto I
    Thromb Haemost; 2018 May; 118(5):852-863. PubMed ID: 29618159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
    Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F
    JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clopidogrel Desensitization: Background and Recommendations for Use of a Rapid (4 Hour) Protocol.
    Bulva J; Simon RA
    Curr Vasc Pharmacol; 2019; 17(2):113-118. PubMed ID: 30378498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
    Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J
    BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
    Deharo P; Quilici J; Camoin-Jau L; Johnson TW; Bassez C; Bonnet G; Fernandez M; Ibrahim M; Suchon P; Verdier V; Fourcade L; Morange PE; Bonnet JL; Alessi MC; Cuisset T
    JACC Cardiovasc Interv; 2017 Dec; 10(24):2560-2570. PubMed ID: 29268886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching between P2Y
    Capranzano P; Capodanno D
    Vascul Pharmacol; 2019 May; 116():4-7. PubMed ID: 30876967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.